ClinicalTrials.gg
CompletedNCT02662985PDUSUpdated Dec 7, 2021Results posted

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

A Phase 3 interventional study of AIN457 (secukinumab) and Placebo in Psoriatic Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 33 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing secukinumab in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. secukinumab · Arthritis, Psoriatic.

Enrollment
15th of 26
166 · median 231
Started
2016
with 4 others
Phase 3
16 of 26
1 open now
Registered
12th of 26
by date
Lead sponsor
17 of 26
Novartis Pharmaceuticals

Among the 26 studies testing secukinumab in Arthritis, Psoriatic, this one is the 15th largest by enrollment, is one of 5 that started in 2016, is one of 16 in phase 3, and was the 12th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 26 studies testing secukinumab in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing secukinumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

This study was designed to leverage the sensitivity of ultrasonography available in clinical practice setting to better describe the time course of response to secukinumab (150 mg and 300 mg) on joint synovitis and enthesitis in PsA patients with an inadequate response to non-biologic DMARDs. PDUS changes in joint synovitis will be assessed using the global Outcome Measures in Rheumatology (OMERACT)-European League against Rheumatism (EULAR) synovitis score (GLOESS) and changes in joint enthesitis were assessed using the OMERACT enthesitis score.

Read the detailed description

This was a 52-week, multicenter, international study consisting of a 2 to 4-week Screening period, a 12-week randomized, placebo-controlled double-blind treatment period (Period 1), a 12-week open-label treatment period (Period 2) and a 6-month open-label extension period (Period 3).

Treatment Period 1 is a 12-week placebo-controlled, randomized period primarily designed to demonstrate the early and optimal efficacy of secukinumab vs placebo on joint synovitis using PDUS via the GLOESS and global entheseal score after 12 weeks of treatment.

The main aim of Period 2 was to assess the maintenance or increased magnitude of treatment response on joint synovitis for patients from the original secukinumab groups and to assess the time course of response with secukinumab on joint synovitis in the original placebo group switched to secukinumab from Week 12.

The main aim of Period 3 (extension period) was to allow patients who respond to secukinumab to extend study treatment up to Week 52 or until commercial drug becomes available, whichever occurs sooner.

03

Conditions studied

  • Psoriatic Arthritis

Keywords

  • Power Doppler Ultrasonography
  • Psoriatic Arthritis
  • Enthesitis
  • Synovitis
  • Outcome Measures in Rheumatology
  • Spondyloarthritis Research Consortium of Canada
  • active psoriatic arthritis
  • secukinumab
  • Arthritis
  • GLOESS
  • monoclonal antibody
  • PsA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be able to understand and communicate with the Investigator and comply with the requirements of the study and must provide written, signed and dated before any study assessment is performed.
  2. Male or female patients at least 18 years of age.
  3. Diagnosis of PsA as per CASPAR with active PsA for at least 6 months and a TJC ≥ 3 of 78 and SJC ≥ 3 of 76 at Baseline.
  4. Patients must have a total synovitis PDUS score ≥ 2 and inflammation related to PD signal ≥ 1 for at least 2 (affected joints as observed via PDUS) of 48 joints at the Screening visit and at the Baseline visit (before infusion).
  5. At least 1 clinically-involved enthesitis site at Screening and at the Baseline visit (before infusion) defined by SPARCC index different from 0.

Exclusion criteria

Exclusion Criteria:

  1. Chest X-ray or chest MRI with evidence of ongoing infectious or malignant process obtained within 3 months prior to Screening and evaluated by a qualified physician.
  2. Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or IL-17 receptor.
  3. Any change in the dose of oral in the last 4 weeks prior to the Baseline visit or use of i.v. intramuscular or intra-articular corticosteroid during the last 4 weeks prior to the enrollment visit.
  4. Patients who have previously been treated with TNFα inhibitors ( or approved).
  5. History of to the study drug or its or to drugs of similar classes.
  6. Previous treatment with any cell-depleting therapies including but not limited to anti CD20 investigational agents (e.g. CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti CD19).
  7. Prohibited psoriasis treatments/medications with topical corticosteroids in the last 4 weeks prior to randomization.
  8. Pregnant or nursing (lactating) women.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
166 participants (actual)

Study arms

  • Active comparator
    Group 1

    In Treatment Period-1: Patients in this group were administered secukinumab with 12 weeks of treatment from baseline. In Treatment Period-2: Patients continued to receive the same active dose of secukinumab every 4 weeks until Week 24 In Treatment Period 3 (extension period): the extension period allowed responder patients the possibility to continue open-label secukinumab treatment up to Week 52

    Drug: AIN457 (secukinumab)

  • Placebo comparator
    Group 2

    In Treatment Period-1: Patients received placebo at baseline and same time points as secukinumab until Week 8. In Treatment Period-2: Patients commenced open-label secukinumab every 4 weeks from Week 12, as follows, based on their clinical characteristics at Week 12 In Treatment Period-3: Open-label secukinumab continued to be assigned to patients

    Drug: AIN457 (secukinumab) · Drug: Placebo

Interventions

  • Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis. Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose was administered as 2 × PFS injections.

    Also known as: Secukinumab

  • DrugPlacebo

    Secukinumab placebo was provided in a 1 mL PFS for s.c. injection.

06

What researchers measure

Primary outcomes

  1. Difference Between Secukinumab and Placebo in Terms of Joint Synovitis as Measured by the Power Doppler Ultrasonography (PDUS) Global OMERACT-EULAR Synovitis Score (GLOESS)

    Mixed model repeated measures (MMRM) analysis of change in Global OMERACT-EULAR Synovitis Score (GLOESS) score at Week 12 (observed data) to compare treatments The range for the GLOESS score is 0 to 144. GLOESS is the ultrasound scoring system measured for 24 pairs of joints. The scoring is from 0 to 3 for each joint; so the minimum score can be 0 and maximum can be 144.

    Time frame: 12 weeks

Secondary outcomes

  1. Proportion of Participants With American College of Rheumatology (ACR)-20 Response

    ACR 20 responder has ≥ 20% improvement in TJC and SJC and \>20% improvement in 3 of the following 5 domains: patient's assessment of disease activity, physician's assessment of disease activity, patient's

    Time frame: Week 12

  2. Proportion of Participants With American College of Rheumatology (ACR)-50 Response

    ACR 50 responder has ≥ 50% improvement in TJC and SJC and \>25% improvement in 3 of the following 5 domains: patient's assessment of disease activity, physician's assessment of disease activity, patient's assessment of PsA pain, HAQ-DI, or hsCRP.

    Time frame: Week 12

  3. Spondyloarthritis Research Consortium of Canada (SPARCC)

    Repeated measures mixed effect (MMRM) analysis of SPARCC total score change from baseline to Week 12 between the 2 treatment groups. SPARCC index ranges from 0 to 16.

    Time frame: Baseline to Week 12

07

Results

Posted Dec 7, 2021

Participant flow

166 participants enrolled in 17 countries

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneGroup 1 - Secukinumab (150 mg + 300 mg)Group 2 - Placebo/Secukinumab
Started8383
Completed8279
Not completed14
Withdrew: Adverse event02
Withdrew: Protocol violation01
Withdrew: Physician decision10
Withdrew: Withdrawal by subject01
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneGroup 1 - Secukinumab (150 mg + 300 mg)Group 2 - Placebo/Secukinumab
Started8279
Completed8178
Not completed11
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up10
Treatment Period 3 (Extension Period)
Participant flow — Treatment Period 3 (Extension Period)
MilestoneGroup 1 - Secukinumab (150 mg + 300 mg)Group 2 - Placebo/Secukinumab
Started8178
Completed7569
Not completed69
Withdrew: Withdrew before entering period44
Withdrew: Adverse event11
Withdrew: Lack of efficacy01
Withdrew: Withdrawal by subject12
Withdrew: Death01

Outcome measures

PrimaryDifference Between Secukinumab and Placebo in Terms of Joint Synovitis as Measured by the Power Doppler Ultrasonography (PDUS) Global OMERACT-EULAR Synovitis Score (GLOESS)

Mixed model repeated measures (MMRM) analysis of change in Global OMERACT-EULAR Synovitis Score (GLOESS) score at Week 12 (observed data) to compare treatments The range for the GLOESS score is 0 to 144. GLOESS is the ultrasound scoring system measured for 24 pairs of joints. The scoring is from 0 to 3 for each joint; so the minimum score can be 0 and maximum can be 144.

Time frame:
12 weeks
Reported as:
Mean · Adjusted Mean Change in scores
Difference Between Secukinumab and Placebo in Terms of Joint Synovitis as Measured by the Power Doppler Ultrasonography (PDUS) Global OMERACT-EULAR Synovitis Score (GLOESS)
Adjusted Mean Change in scoresGroup 1 - Secukinumab (150 mg + 300 mg)Group 2 - Placebo/Secukinumab
Difference Between Secukinumab and Placebo in Terms of Joint Synovitis as Measured by the Power Doppler Ultrasonography (PDUS) Global OMERACT-EULAR Synovitis Score (GLOESS)-9.05 ± 0.94-5.86 ± 0.93
Statistical analysis
  • Group 1 - Secukinumab (150 mg + 300 mg) vs Group 2 - Placebo/Secukinumab · Mixed Models Analysis · p = 0.0040 · Median difference (net): -3.18 · 95% CI -5.52 to -0.85mixed model repeated measures (MMRM)
SecondaryProportion of Participants With American College of Rheumatology (ACR)-20 Response

ACR 20 responder has ≥ 20% improvement in TJC and SJC and \>20% improvement in 3 of the following 5 domains: patient's assessment of disease activity, physician's assessment of disease activity, patient's

Time frame:
Week 12
Reported as:
Count of participants · Participants
Proportion of Participants With American College of Rheumatology (ACR)-20 Response
ParticipantsGroup 1 - Secukinumab (150 mg + 300 mg)Group 2 - Placebo/Secukinumab
Proportion of Participants With American College of Rheumatology (ACR)-20 Response5626
Statistical analysis
  • Group 1 - Secukinumab (150 mg + 300 mg) vs Group 2 - Placebo/Secukinumab · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.60 · 95% CI 2.38 to 8.89Logistic regression using non-responder imputation
SecondaryProportion of Participants With American College of Rheumatology (ACR)-50 Response

ACR 50 responder has ≥ 50% improvement in TJC and SJC and \>25% improvement in 3 of the following 5 domains: patient's assessment of disease activity, physician's assessment of disease activity, patient's assessment of PsA pain, HAQ-DI, or hsCRP.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Proportion of Participants With American College of Rheumatology (ACR)-50 Response
ParticipantsGroup 1 - Secukinumab (150 mg + 300 mg)Group 2 - Placebo/Secukinumab
Proportion of Participants With American College of Rheumatology (ACR)-50 Response387
Statistical analysis
  • Group 1 - Secukinumab (150 mg + 300 mg) vs Group 2 - Placebo/Secukinumab · Regression, Logistic · p = <0.0001 · Odds ratio (or): 9.65 · 95% CI 3.92 to 23.75
SecondarySpondyloarthritis Research Consortium of Canada (SPARCC)

Repeated measures mixed effect (MMRM) analysis of SPARCC total score change from baseline to Week 12 between the 2 treatment groups. SPARCC index ranges from 0 to 16.

Time frame:
Baseline to Week 12
Reported as:
Mean · Adjusted mean change in scores
Spondyloarthritis Research Consortium of Canada (SPARCC)
Adjusted mean change in scoresGroup 1 - Secukinumab (150 mg + 300 mg)Group 2 - Placebo/Secukinumab
Spondyloarthritis Research Consortium of Canada (SPARCC)-2.23 ± 0.29-1.57 ± 0.29
Statistical analysis
  • Group 1 - Secukinumab (150 mg + 300 mg) vs Group 2 - Placebo/Secukinumab · Regression, Logistic · p = 0.0327 · Adjusted mean of treatment difference: -0.67 · 95% CI -1.374 to 0.043

Adverse events

Collected over AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for 12 weeks. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 52 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Group 1 - Secukinumab (150+300 mg)1/161 (0.6%)9/161 (5.6%)79/161 (49.1%)
Treatnent Group 2 - Placebo/Secukinumab0/83 (0%)2/83 (2.4%)27/83 (32.5%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventTreatment Group 1 - Secukinumab (150+300 mg)Treatnent Group 2 - Placebo/Secukinumab
Acute myocardial infarctionCardiac disorders2/1610/83
DiarrhoeaGastrointestinal disorders0/1611/83
Femur fractureInjury, poisoning and procedural complications0/1611/83
Atrial fibrillationCardiac disorders1/1610/83
Coronary artery stenosisCardiac disorders1/1610/83
COVID-19Infections and infestations1/1610/83
Incisional herniaInjury, poisoning and procedural complications1/1610/83
MalnutritionMetabolism and nutrition disorders1/1610/83
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1610/83
Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1610/83
Most frequent other events
Showing 10 of 24
Most frequent other events
EventTreatment Group 1 - Secukinumab (150+300 mg)Treatnent Group 2 - Placebo/Secukinumab
NasopharyngitisInfections and infestations19/1614/83
HeadacheNervous system disorders13/1613/83
DiarrhoeaGastrointestinal disorders7/1616/83
Urinary tract infectionInfections and infestations10/1613/83
CoughRespiratory, thoracic and mediastinal disorders9/1612/83
HypertensionVascular disorders9/1611/83
BronchitisInfections and infestations8/1612/83
InfluenzaInfections and infestations7/1613/83
Dry eyeEye disorders3/1613/83
Abdominal painGastrointestinal disorders5/1613/83

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group 1 - Secukinumab (150 mg + 300 mg)Group 2 - Placebo/Secukinumab (150 mg + 300 mg)Total
<=18 years000
Between 18 and 65 years7679155
>=65 years7411
Age, Continuous
Age, Continuous(years)Group 1 - Secukinumab (150 mg + 300 mg)Group 2 - Placebo/Secukinumab (150 mg + 300 mg)Total
Mean46.7 ± 12.3546.7 ± 12.0846.7 ± 12.18
Sex: Female, Male
Sex: Female, Male(Participants)Group 1 - Secukinumab (150 mg + 300 mg)Group 2 - Placebo/Secukinumab (150 mg + 300 mg)Total
Female454691
Male383775
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1 - Secukinumab (150 mg + 300 mg)Group 2 - Placebo/Secukinumab (150 mg + 300 mg)Total
Caucasian7575150
Asian101
Native American4812
Unknown202
Other101
08

Study locations

33 sites
  • Novartis Investigative Site
    Beverly Hills, California 90211, United States
  • Novartis Investigative Site
    Los Angeles, California 90095, United States
  • Novartis Investigative Site
    Wheaton, Maryland 20902, United States
  • Novartis Investigative Site
    Salt Lake City, Utah 84102, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1181ACH, Argentina
  • Novartis Investigative Site
    Ciudad Autonoma de Bs As, C1428AZF, Argentina
  • Novartis Investigative Site
    Tucuman, 4000, Argentina
  • Novartis Investigative Site
    Vienna, 1040, Austria
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Ghent, 9000, Belgium
  • Novartis Investigative Site
    Toronto, Ontario M5T 2S8, Canada
  • Novartis Investigative Site
    Bogota, Cundinamarca, Colombia
  • Novartis Investigative Site
    Prague 2, Czech Republic 128 50, Czechia
  • Novartis Investigative Site
    Boulogne Billancourt, 92104, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Paris, 75651, France
  • Novartis Investigative Site
    Berlin, 13086, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Miskolc, Baz 3529, Hungary
  • Novartis Investigative Site
    Dublin 4, 4, Ireland
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Genova, 16132, Italy
  • Novartis Investigative Site
    Pisa, 56126, Italy
  • Novartis Investigative Site
    Mexico, Ciudad De Mexico 06700, Mexico
  • Novartis Investigative Site
    Guadalajara Jalisco, 44610, Mexico
  • Novartis Investigative Site
    Amsterdam, 1081 HV, Netherlands
  • Novartis Investigative Site
    Oslo, 0319, Norway
  • Novartis Investigative Site
    Barcelona, 08022, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Madrid, 28935, Spain
  • Novartis Investigative Site
    Leeds, West Yorkshire LS7 4SA, United Kingdom
09

References and documents

Publications

  • D'Agostino MA, Schett G, Lopez-Rdz A, Senolt L, Fazekas K, Burgos-Vargas R, Maldonado-Cocco J, Naredo E, Carron P, Duggan AM, Goyanka P, Boers M, Gaillez C. Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE. Rheumatology (Oxford). 2022 May 5;61(5):1867-1876. doi: 10.1093/rheumatology/keab628. PubMed 34528079 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Nov 2020, 50 months.

Results were first posted in Dec 2021, 1 year after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 50 months is above that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2016
First posted
Jan 26, 2016
StartActual
Aug 22, 2016
Primary completionActual
Nov 10, 2020
CompletionActual
Nov 10, 2020
Results first posted
Dec 7, 2021
Last update
Dec 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02662985
Responsible party
Sponsor
First posted
Jan 26, 2016
Start date
Aug 22, 2016
Primary completion
Nov 10, 2020
Completion
Nov 10, 2020
Results posted
Dec 7, 2021
Last update
Dec 7, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion